Whether you live with chronic inflammatory demyelinating polyneuropathy (CIDP) or are a caregiver, My VYVGART Path has resources to help you feel supported throughout the treatment journey.
See how the My VYVGART Path Patient Support Program can empower you on your VYVGART Hytrulo treatment journey.
Fill out this form once you have been prescribed VYVGART Hytrulo to enroll yourself in My VYVGART Path.
This brochure contains important information about VYVGART Hytrulo. Learn about how it works, effectiveness and safety data, dosing, and much more!
Discover caregiver-specific education about VYVGART Hytrulo, self-care tips, and resources.
See if you could be eligible to pay as little as $0 for your co-pay through the VYVGART Co-pay Program.*
*Eligible commercially insured patients may pay as little as $0 for VYVGART Hytrulo and may receive a maximum benefit of $25,000 per calendar year for their eligible out-of-pocket costs for the drug and drug administration. Persons residing in MA and RI are not eligible for financial assistance related to administration costs. Please see full Terms and Conditions.
The “What’s Next?” patient guide outlines what you can expect as you begin your journey with VYVGART Hytrulo, from navigating insurance to starting your first treatment.
Learn about the insurance process and see how the My VYVGART Path team may assist you in accessing VYVGART Hytrulo.
Information about dosing and how to prepare for your VYVGART Hytrulo subcutaneous injection.
Use this card to share treatment information and key contacts in the case of an emergency.
CIDP=chronic inflammatory demyelinating polyneuropathy
Do not use VYVGART HYTRULO if you have a serious allergy to efgartigimod alfa, hyaluronidase, or any of the other ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.
Tell your doctor if you have signs or symptoms of an infection, allergic reaction, or infusion-related reaction. These can happen while you are receiving your VYVGART HYTRULO treatment or afterward. Your doctor may need to pause or stop your treatment. Contact your doctor immediately if you have signs or symptoms of a serious allergic reaction.
The most common side effects in efgartigimod-alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. Additional common side effects with VYVGART HYTRULO are injection site reactions, including rash, redness of the skin, itching sensation, bruising, pain, and hives.
These are not all the possible side effects of VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1-800-FDA-1088.
VYVGART HYTRULO is a prescription medicine used for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP)
Do not use VYVGART HYTRULO if you have a serious allergy to efgartigimod alfa, hyaluronidase, or any of the other ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.
Tell your doctor if you have signs or symptoms of an infection, allergic reaction, or infusion-related reaction. These can happen while you are receiving your VYVGART HYTRULO treatment or afterward. Your doctor may need to pause or stop your treatment. Contact your doctor immediately if you have signs or symptoms of a serious allergic reaction.
The most common side effects in efgartigimod-alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. Additional common side effects with VYVGART HYTRULO are injection site reactions, including rash, redness of the skin, itching sensation, bruising, pain, and hives.
These are not all the possible side effects of VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1-800-FDA-1088.
VYVGART HYTRULO is a prescription medicine used for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP)